EFPIA highlights 17 billion euros cost of counterfeit drugs

30 September 2016

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted the findings of a new report in calling for a global response to the problem of counterfeit medicines.

Published by the European Observatory on Infringements of Intellectual Property Rights and titled The economic cost of IPR infringement in the pharmaceutical industry, the report assesses the financial impact of counterfeiting and piracy in the sector and underscores the serious public health threat it poses.

Estimates suggest that 10% of all medicines supplied globally are falsified

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK